Progenity to Showcase New Data at Digestive Disease Week®

SAN DIEGO–(BUSINESS WIRE)–Progenity,
Inc., a privately held biotechnology company developing precision
medicine solutions across genomic/epigenomic, proteomic, and microbiomic
diagnostic and therapeutic platforms, this week announced three upcoming
poster presentations.

Alongside their women’s health products, Progenity has an extensive and
innovative pipeline of ingestible molecular diagnostics and therapeutic
products in development for gastrointestinal disorders, such as
inflammatory bowel disease and small intestinal bacterial overgrowth.
Progenity will be presenting three posters at Digestive Disease Week^®
2019 held May 18-21 in San Diego, California:

Title: Development of a Swallowable Diagnostic Capsule to Monitor
Gastrointestinal Health
Presenting Author: Mitchell Jones,
M.D., Ph.D., Vice President, Translation and Clinical Development at
Progenity
Session: Advanced Imaging of the Upper and Lower GI Tract
Date
and Time: May 18, 2019; 12:00 PM – 2:00 PM PDT
Poster Number: Sa1717
Location:
Poster Hall, San Diego Convention Center

Title: Development of Targeted Therapeutic Antibodies for the
Treatment of Inflammatory Bowel Disease
Presenting Author:
Mitchell Jones, M.D., Ph.D., Vice President, Translation and Clinical
Development at Progenity
Session: IBD – Comparative Effectiveness
Studies
Date and Time: May 19, 2019; 12:00 PM – 2:00 PM PDT
Poster
Number: Su1875
Location: Poster Hall, San Diego Convention Center

Title: A Comparison Study of Systemic Versus Targeted Intracecal
Anti-TNFα Monoclonal Antibody in an Adoptive T-cell Transfer Murine
Model of Colitis
Author: Mitchell Jones, M.D., Ph.D., Vice
President, Translation and Clinical Development at Progenity
Session:
Animal Models – Preclinical Treatment of Intestinal Inflammation
Date
and Time: May 19, 2019; 12:00 PM – 2:00 PM PDT
Poster Number: Su1809
Location:
Poster Hall, San Diego Convention Center

More information about these studies will be made available on the Progenity
website following the conference.

About DDW
Digestive Disease Week^® (DDW) is the
largest international gathering of physicians, researchers and academics
in the fields of gastroenterology, hepatology, endoscopy and
gastrointestinal surgery. Jointly sponsored by the American Association
for the Study of Liver Diseases (AASLD), the American
Gastroenterological Association (AGA) Institute, the American Society
for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the
Alimentary Tract (SSAT), DDW takes place May 18-21, 2019, at the San
Diego Convention Center. The meeting showcases more than 5,000 abstracts
and hundreds of lectures on the latest advances in GI research, medicine
and technology. More information can be found at www.ddw.org.

About Progenity
Progenity, Inc., is a privately held
biotechnology company with the mission of transforming healthcare to be
more precise and personal. The company is translating innovation into
precision medicine through diagnostic and therapeutic development
platforms based on genomics/epigenomics, proteomics, and microbiomics.
These platforms feed an R&D pipeline of innovative products designed to
improve patient outcomes in prenatal and perinatal healthcare settings,
oncology, and gastroenterology. Progenity’s ultimate vision is to make
precision medicine a reality by both diagnosing disease at its source
and treating it with targeted therapies developed by the company.
Progenity is headquartered in San Diego, California. For more
information on how Progenity is helping clinicians and patients prepare
for life, please visit www.progenity.com.

Contacts

Media Contact
Nicole Goelz
CG Life
[email protected]
(858)
457-2436

Investor Contact
[email protected]